Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast version of Five Must-Know Things: GSK boosts vaccine presence via M&A; US PBM formulary exclusions on the rise; ASCO data portend battle for bispecifics in lymphoma; mixed ASCO data for Cabometyx combos; and Junshi’s oral COVID-19 antiviral shows promise although questions remain.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 3 June 2022, including: GlaxoSmithKline plc boosts vaccine presence via M&A; US PBM formulary exclusions on the rise; ASCO data portend battle for bispecifics in lymphoma; mixed ASCO data for Cabometyx combos; and Shanghai Junshi Biosciences Co., Ltd.’s oral COVID antiviral shows promise although questions remain.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "GSK Spies Pfizer Challenge With $2.1bn Vaccine Company Acquisition" - Scrip, 31 May, 2022.)
(Also see "PBM Formulary Exclusions On The Rise, PhRMA Says" - Scrip, 26 May, 2022.)
(Also see "ASCO Data Show A Battle Ahead For Roche And Genmab’s Lymphoma Bispecifics" - Scrip, 27 May, 2022.)
(Also see "Exelixis’s Cabometyx Plus Tecentriq Disappoints In Lung Cancer" - Scrip, 27 May, 2022.)
(Also see "Junshi’s COVID Antiviral Superior To Paxlovid? Some Caveats Unveiled" - Scrip, 29 May, 2022.)